Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients
A Phase I Open-label, Randomized, Safety and Efficacy Study of SANGUINATE™ at Two Doses Levels Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients.
Sponsor: Prolong Pharmaceuticals
A PHASE1 clinical study on Sickle Cell Disease, this trial is completed. The trial is conducted by Prolong Pharmaceuticals and has accumulated 8 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE1
-
Sep 2025 — Nov 2025 [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
May 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Prolong Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .